公开(公告)号：US20140100369A1

公开(公告)日：2014-04-10

申请号：US13974895

申请日：2013-08-23

申请人： Array BioPharma Inc.

发明人： Yvan Le Huerou ,  James F. Blake ,  Indrani W. Gunawardana ,  Peter J. Mohr ,  Eli M. Wallace ,  Bin Wang ,  Mark Joseph Chicarelli ,  Michael Lyon

IPC分类号： C07D471/04

CPC分类号： C07D471/04 ,  C07D401/06 ,  C07D519/00

摘要： Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20130252934A1

公开(公告)日：2013-09-26

申请号：US13782513

申请日：2013-03-01

申请人： ARRAY BIOPHARMA INC. ,  GENENTECH, INC.

发明人： James F. Blake ,  Mark Joseph Chicarelli ,  Rustam Ferdinand Garrey ,  John Gaudino ,  Jonas Grina ,  David A. Moreno ,  Peter J. Mohr ,  Li Ren ,  Jacob Schwarz ,  Huifen Chen ,  Kirk Robarge ,  Aihe Zhou

IPC分类号： A61K31/506 ,  C07D401/04 ,  A61K45/06 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D405/14 ,  C07D401/14

CPC分类号： C07D401/04 ,  A61K31/444 ,  A61K31/506 ,  A61K31/513 ,  A61K31/53 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07F9/65586

摘要： Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

摘要翻译： 提供式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐，其可用于治疗过度增生，疼痛和炎性疾病。 公开了使用式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US11851434B2

公开(公告)日：2023-12-26

申请号：US17514684

申请日：2021-10-29

申请人： Array BioPharma Inc.

发明人： Steven W. Andrews ,  James F. Blake ,  Julia Haas ,  Yutong Jiang ,  Gabrielle R. Kolakowski ,  David A. Moreno ,  Li Ren ,  Shane M. Walls

IPC分类号： A61K31/4985 ,  C07D487/04

CPC分类号： C07D487/04

摘要： Provided herein are compounds of the Formula I:




and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

公开(公告)号：US11472802B2

公开(公告)日：2022-10-18

申请号：US16962305

申请日：2019-01-18

申请人： Array BioPharma Inc.

发明人： Shane M. Walls ,  Li Ren ,  Ginelle A. Ramann ,  David A. Moreno ,  Andrew T. Metcalf ,  Elizabeth A. McFaddin ,  Gabrielle R. Kolakowski ,  James F. Blake ,  Donghua Dai ,  Julia Haas ,  Yutong Jiang ,  Dean Kahn

IPC分类号： C07D471/04 ,  A61P35/00 ,  C07F9/6561

摘要： Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US10889589B2

公开(公告)日：2021-01-12

申请号：US16415575

申请日：2019-05-17

申请人： Array BioPharma Inc.

发明人： Shelley Allen ,  Steven Wade Andrews ,  James F. Blake ,  Barbara J. Brandhuber ,  Julia Haas ,  Yutong Jiang ,  Timothy Kercher ,  Gabrielle R. Kolakowski ,  Allen A. Thomas ,  Shannon L. Winski

IPC分类号： C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D491/048 ,  C07D231/40 ,  C07D231/54 ,  C07D401/12 ,  C07D403/02 ,  C07D403/04 ,  C07D405/12 ,  C07D413/12 ,  C07D453/02 ,  C07D231/52 ,  C07D231/56 ,  C07D401/04 ,  C07D409/14 ,  C07D471/08

摘要： Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

公开(公告)号：US10724102B2

公开(公告)日：2020-07-28

申请号：US15335378

申请日：2016-10-26

申请人： Loxo Oncology, Inc. ,  Array BioPharma, Inc.

发明人： Nisha Nanda ,  Joshua H. Bilenker ,  James F. Blake ,  Gabrielle R. Kolakowski ,  Barbara J. Brandhuber ,  Steven W. Andrews

IPC分类号： C12Q1/6886 ,  A61K31/5025 ,  A61K31/519 ,  G01N33/574

摘要： Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.

公开(公告)号：US10688100B2

公开(公告)日：2020-06-23

申请号：US16199875

申请日：2018-11-26

申请人： Array BioPharma Inc.

发明人： Steven W. Andrews ,  James F. Blake ,  Julia Haas ,  Gabrielle R. Kolakowski

IPC分类号： A61K31/529 ,  A61K31/519 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/675

摘要： Methods for inhibiting a ROS1 kinase with compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein. The compounds and methods provided herein are useful in the treatment of cancer (e.g., ROS1-associated cancers as defined herein).

公开(公告)号：US10519126B2

公开(公告)日：2019-12-31

申请号：US15625297

申请日：2017-06-16

申请人： Array BioPharma Inc. ,  Genentech, Inc.

发明人： James F. Blake ,  Mark Joseph Chicarelli ,  Rustam Ferdinand Garrey ,  John Gaudino ,  Jonas Grina ,  David A. Moreno ,  Peter J. Mohr ,  Li Ren ,  Jacob Schwarz ,  Huifen Chen ,  Kirk Robarge ,  Aihe Zhou

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6558 ,  C07D403/04 ,  A61K31/513 ,  A61K31/53 ,  A61K31/444

摘要： Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US10370727B2

公开(公告)日：2019-08-06

申请号：US15785174

申请日：2017-10-16

申请人： Loxo Oncology, Inc. ,  Array BioPharma, Inc.

发明人： Nisha Nanda ,  Joshua H. Bilenker ,  James F. Blake ,  Gabrielle R. Kolakowski ,  Barbara J. Brandhuber ,  Steven W. Andrews

IPC分类号： C12Q1/6886 ,  A61K31/5025 ,  A61K31/519 ,  G01N33/574

摘要： Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.

公开(公告)号：US20190151322A1

公开(公告)日：2019-05-23

申请号：US16199818

申请日：2018-11-26

申请人： Array BioPharma Inc.

发明人： Steven W. Andrews ,  James F. Blake ,  Julia Haas ,  Gabrielle R. Kolakowski

IPC分类号： A61K31/529 ,  A61K31/496 ,  A61K31/675 ,  A61K31/4545 ,  A61P35/00

摘要： Methods for inhibiting a ROS1 kinase with compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein. The compounds and methods provided herein are useful in the treatment of cancer (e.g., ROS1-associated cancers as defined herein).